CorMedix (NYSE: CRMD) is an emerging commercial-stage biopharmaceutical company that initiated a phase 3 clinical study of a novel anti-infective solution in hemodialysis patients. The company’s strategy is to seek to in-license, develop and commercialize therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The initial and planned indications aim to address significant needs in catheter-based treatments in the U.S. and the rest of the world. For more information, visit the company’s website at www.cormedix.com.